Focus on HIV Care

Back to articles

Experts debate emtricitabine/tenofovir approval for HIV prevention

KEY POINT

FDA Advisory Committee members debated the pros and cons of the recently approved indication to use emtricitabine/tenofovir (Truvada—Gilead) for HIV pre-exposure prophylaxis (PrEP) in recent commentaries. Authors of an accompanying review acknowledged ongoing concerns with this agent, but provided guidance for its appropriate use and monitoring for HIV prevention.

SOURCES

Feinberg J. Preexposure prophylaxis for HIV. Ann Intern Med. 2012; [epub ahead of print].

Wood LV. Why I voted “no” to Truvada PrEP. Ann Intern Med. 2012; [epub ahead of print].

Krakower D et al. Preexposure prophylaxis for HIV prevention: what primary care providers need to know about preexposure prophylaxis for HIV prevention. Ann Intern Med. 2012; [epub ahead of print].

Steinbrook R. Preexposure prophylaxis for HIV Infection. JAMA. 2012; [epub ahead of print].